• 16 April, 2025
BioNTech Reports Strong H1 2024 with Key Advances in COVID-19 Vaccines, Oncology Pipeline, and Strategic Partnerships

BioNTech SE (Nasdaq: BNTX), a global leader in immunotherapy and innovative vaccine development, has reported significan...

September 2, 2024 | Monday | Analysis
Biogen Strengthens Leadership in Neurology and Immunology Through Strategic Initiatives and Clinical Advancements in H1 2024

Biogen's activities from January to June 2024 reflect a period of strategic initiatives, clinical advancements, and or...

September 2, 2024 | Monday | Analysis
Amgen’s 2024 Surge: Regulatory Triumphs, Innovative Therapies, and Robust Financial Growth

  From January to June 2024, Amgen demonstrated significant progress across various therapeutic areas, product lau...

September 2, 2024 | Monday | Analysis

Podcast

Most Read

Survey Box

Is the CDMO sector ramping up its environmental responsibility?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls